Market Access Impact (EU5) [PsO]
|市場進入的課題:乾癬 (歐盟5國) Market Access Impact (EU5) [PsO]|
|出版日期: 2017年03月01日||內容資訊: 英文||
Eliminating market barriers could lift the last place brand into the middle of the pack
In the EU5 countries, market barriers affect nearly a quarter of psoriasis prescriptions. Most of the brands we surveyed gain or lose a little bit of market share, but one brand is having a much harder time of it. If it can find a way to overcome market barriers, this brand could climb from dead last to somewhere in the middle of the pack.
Find out whether breaking down market barriers can give your brand a boost in Market Access Impact: Psoriasis (EU5).
Based on a survey of 150 dermatologists, the report covers 10 major therapies from AbbVie, Biogen, Celgene, EliLilly, Janssen Cilag, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Insight into 10 Major Psoriasis Drugs
Exploring Important Market Access Issues
Market Access Impact: Psoriasis (EU5) explores key issues affecting drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 150 dermatologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.
All respondents have:
We conducted the survey between February 1st and 7th, 2017.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.